UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 263

Sortiert nach

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption

Bone Reports, 2019-06, Vol.10, p.100201-100201, Article 100201

2019

Volltextzugriff (PDF)

Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines

Cancers, 2018-04, Vol.10 (4), p.127

2018

Volltextzugriff (PDF)

Selective Btk inhibitor, ONO/GS-4059: Preclinical evidence supporting the combination with Idelalisib and obinutuzumab

Annals of oncology, 2016-11, Vol.27, p.vii30

Yoshizawa, Toshio

2016

Volltextzugriff (PDF)

Abstract LB-259: The potent and selective Axl/Mer dual inhibitor ONO-9330547, shows promising single agent activity in non-small cell lung cancer (NSCLC)

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.LB-259-LB-259

2015

Volltextzugriff (PDF)

Development of an Axl/Mer Dual Inhibitor, ONO-9330547: Promising Single Agent Activity in an Acute Myeloid Leukemia (AML) Model

Blood, 2014-12, Vol.124 (21), p.999-999

2014

Volltextzugriff (PDF)

Synoviocyte Innate Immune Responses: I. Differential Regulation of Interferon Responses and the JNK Pathway by MAPK Kinases

The Journal of immunology (1950), 2008-09, Vol.181 (5), p.3252-3258

2008

Volltextzugriff (PDF)

Abstract 2021: ONO-WG-307, a novel, potent and selective inhibitor of Bruton's tyrosine kinase (Btk), results in sustained inhibition of the ERK, AKT and PKD signaling pathways

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2021-2021

2012

Volltextzugriff (PDF)

Forecast of stock market based on nonharmonic analysis used on NASDAQ since 1985

Applied financial economics, 2012-02, Vol.22 (3), p.197-208

2012

Volltextzugriff (PDF)

Abstract 3727: Plasma inhibitory activity (PIA) is a possible pharmacodynamic marker for clinical development of a next generation pan-TRK inhibitor, ONO-5390556

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3727-3727

2017

Volltextzugriff (PDF)

Abstract 2954A: A potent and selective TRK inhibitor ONO-5390556, shows potent antitumor activity against both TRK-rearranged cancers and the resistant mutants

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2954-2954A

2016

Volltextzugriff (PDF)

Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab

Leukemia & lymphoma, 2017-03, Vol.58 (3), p.699-707

2017

Volltextzugriff (PDF)

Abstract 788: A novel, potent and selective pan-Trk inhibitor ONO-5390556, demonstrates therapeutic efficacy in cancer cells harboring the TrkA rearrangement

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.788-788

2015

Volltextzugriff (PDF)

Abstract 1883: A novel Axl and Mertk dual inhibitor ONO-7475: A new therapeutic agent for the treatment of FLT3-ITD and -wild-type acute myeloid leukemia (AML) overexpressing

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1883-1883

2018

Volltextzugriff (PDF)

ONO-4059—a Potent and Selective Reversible Bruton’s Tyrosine Kinase (Btk) Inhibitor: Single Agent, Twice Daily (BD) Dosing and Dosing with Food Results in Sustained, High Trough Levels of ONO-4059, Translating into 100% Tumour Remission in a TMD-8 Xenograft Model

Blood, 2014-12, Vol.124 (21), p.4502-4502

2014

Volltextzugriff (PDF)

TAM Inhibitor ONO-7475 Combination with Sorafenib Is Effective Using in Vitro and In Vivo Models of FLT3 ITD Acute Myeloid Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.2642-2642

2018

Volltextzugriff (PDF)

Abstract LB-218: Development of AxlMer inhibitor, ONO-9330547: preclinical evidence supporting the combination with immunotherapeutics

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.LB-218-LB-218

2016

Volltextzugriff (PDF)

Abstract LB-218: Development of Axl/Mer inhibitor, ONO-9330547: preclinical evidence supporting the combination with immunotherapeutics

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.LB-218-LB-218

2016

Volltextzugriff (PDF)

Motion Analysis Using 3D High-Resolution Frequency Analysis

IEEE transactions on image processing, 2013-08, Vol.22 (8), p.2946-2959

2013

Volltextzugriff (PDF)

AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells

Blood, 2019-11, Vol.134 (Supplement_1), p.2550-2550

2019

Volltextzugriff (PDF)

Image Inpainting on the Basis of Spectral Structure From 2-D Nonharmonic Analysis

IEEE transactions on image processing, 2013-08, Vol.22 (8), p.3008-3017

2013

Volltextzugriff (PDF)

A catalytic subunit of calpain possesses full proteolytic activity

FEBS letters, 1995-01, Vol.358 (1), p.101-103

1995

Volltextzugriff (PDF)

CXCL12 Enhances CLL Cell and T-Cell Migration in a Dynamic Circulating Model of CLL That Can be Abrogated By the CXCR4 Antagonist ONO-7161

Blood, 2014-12, Vol.124 (21), p.3293-3293

2014

Volltextzugriff (PDF)

AXL Inhibitor ONO-9330547 Suppresses PLK1 Gene and Protein Expression and Effectively Induces Growth Arrest and Apoptosis in FLT3 ITD Acute Myeloid Leukemia Cells

Blood, 2016-12, Vol.128 (22), p.3939-3939

2016

Volltextzugriff (PDF)

Autolysis of Calpain Large Subunit Inducing Irreversible Dissociation of Stoichiometric Heterodimer of Calpain

Bioscience, biotechnology, and biochemistry, 2000-01, Vol.64 (4), p.689-695

2000

Volltextzugriff (PDF)

1 – 25 von 263

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLink (Online service)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(153)
Mit Volltextzugriff
(254)

Publikationsform

Sprache

Englisch
(213)
Japanisch
(122)

Erscheinungsjahr

n.n

Thema

Science & Technology
(94)
Life Sciences & Biomedicine
(56)
Humans
(33)
Physical Sciences
(30)
Physics
(21)
Technology
(21)
Animals
(16)
Male
(15)
Biological And Medical Sciences
(14)
Physics, Applied
(14)
Engineering
(12)
Exact Sciences And Technology
(10)
Female
(10)
Medical Sciences
(10)
Middle Aged
(10)
Engineering, Electrical & Electronic
(9)
Biochemistry & Molecular Biology
(8)
Oncology
(8)
Adult
(7)
Applied Sciences
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption

Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines

Selective Btk inhibitor, ONO/GS-4059: Preclinical evidence supporting the combination with Idelalisib and obinutuzumab

Abstract LB-259: The potent and selective Axl/Mer dual inhibitor ONO-9330547, shows promising single agent activity in non-small cell lung cancer (NSCLC)

Development of an Axl/Mer Dual Inhibitor, ONO-9330547: Promising Single Agent Activity in an Acute Myeloid Leukemia (AML) Model

Synoviocyte Innate Immune Responses: I. Differential Regulation of Interferon Responses and the JNK Pathway by MAPK Kinases

Abstract 2021: ONO-WG-307, a novel, potent and selective inhibitor of Bruton's tyrosine kinase (Btk), results in sustained inhibition of the ERK, AKT and PKD signaling pathways

Forecast of stock market based on nonharmonic analysis used on NASDAQ since 1985

Abstract 3727: Plasma inhibitory activity (PIA) is a possible pharmacodynamic marker for clinical development of a next generation pan-TRK inhibitor, ONO-5390556

Abstract 2954A: A potent and selective TRK inhibitor ONO-5390556, shows potent antitumor activity against both TRK-rearranged cancers and the resistant mutants

Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab

Abstract 788: A novel, potent and selective pan-Trk inhibitor ONO-5390556, demonstrates therapeutic efficacy in cancer cells harboring the TrkA rearrangement

Abstract 1883: A novel Axl and Mertk dual inhibitor ONO-7475: A new therapeutic agent for the treatment of FLT3-ITD and -wild-type acute myeloid leukemia (AML) overexpressing

ONO-4059—a Potent and Selective Reversible Bruton’s Tyrosine Kinase (Btk) Inhibitor: Single Agent, Twice Daily (BD) Dosing and Dosing with Food Results in Sustained, High Trough Levels of ONO-4059, Translating into 100% Tumour Remission in a TMD-8 Xenograft Model

TAM Inhibitor ONO-7475 Combination with Sorafenib Is Effective Using in Vitro and In Vivo Models of FLT3 ITD Acute Myeloid Leukemia

Abstract LB-218: Development of AxlMer inhibitor, ONO-9330547: preclinical evidence supporting the combination with immunotherapeutics

Abstract LB-218: Development of Axl/Mer inhibitor, ONO-9330547: preclinical evidence supporting the combination with immunotherapeutics

Motion Analysis Using 3D High-Resolution Frequency Analysis

AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells

Image Inpainting on the Basis of Spectral Structure From 2-D Nonharmonic Analysis

A catalytic subunit of calpain possesses full proteolytic activity

CXCL12 Enhances CLL Cell and T-Cell Migration in a Dynamic Circulating Model of CLL That Can be Abrogated By the CXCR4 Antagonist ONO-7161

AXL Inhibitor ONO-9330547 Suppresses PLK1 Gene and Protein Expression and Effectively Induces Growth Arrest and Apoptosis in FLT3 ITD Acute Myeloid Leukemia Cells

Autolysis of Calpain Large Subunit Inducing Irreversible Dissociation of Stoichiometric Heterodimer of Calpain

Aktive Filter

Suchergebnisse filtern